Bill
AB 1103
AB 1103 streamlines research approval for controlled substances in California, promoting scientific inquiry while protecting sensitive information and ensuring safety standards.
Bill Number: AB 1103
Author: Ward
Status: Chaptered by Secretary of State - Chapter 571, Statutes of 2025
Introduced: February 20, 2025
Subject: Controlled substances, research
AB 1103 aims to enhance the regulatory framework for research involving controlled substances in California, particularly focusing on Schedule I and Schedule II substances. The bill revises existing laws to streamline the approval process for research projects and extends certain provisions related to confidentiality during the review process.
The primary intent of AB 1103 is to facilitate and expedite research on controlled substances, including cannabis and hallucinogenic drugs. By revising the California Uniform Controlled Substances Act, the bill seeks to promote scientific inquiry while ensuring that safety and regulatory standards are maintained.
Research Advisory Panel Review: The bill mandates that the Research Advisory Panel review all research projects involving the administration of Schedule I or Schedule II controlled substances.
Expedited Review Process: Until January 1, 2028, the panel is authorized to expedite the review of projects that meet specific criteria, such as:
Delegation of Approval: The chairperson of the panel can delegate the review and approval of research projects to two or more panel members, allowing for quicker decisions without requiring a full panel vote.
Withdrawal of Approval: The panel retains the authority to withdraw its approval for reasonable cause, provided that notice is given and time is allowed for the project to address any concerns.
Closed Sessions Extension: The bill extends the authorization for the Research Advisory Panel to hold closed sessions until January 1, 2028, for discussions involving sensitive information, such as trade secrets or proprietary data. Additionally, panel members assigned to expedited reviews are exempt from the Bagley-Keene Open Meeting Act until the same date.
Legislative Findings: The bill includes findings that justify the limitations on public access to certain meetings and documents, emphasizing the need to protect sensitive information.
AB 1103 is expected to:
- Facilitate Research: By streamlining the approval process, the bill aims to encourage more research initiatives involving controlled substances, potentially leading to advancements in medical and therapeutic applications.
Protect Confidentiality: The extension of closed session provisions ensures that sensitive information related to research projects is safeguarded, which may encourage more researchers to engage in studies without fear of public disclosure.
Regulatory Clarity: The bill clarifies the roles and responsibilities of the Research Advisory Panel, which may improve the efficiency of the research approval process.
AB 1103 represents a significant step in enhancing California's research capabilities regarding controlled substances. By revising the approval process and extending confidentiality provisions, the bill aims to foster a more conducive environment for scientific research while maintaining necessary regulatory oversight.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
